R3 Bio Discloses Nonsentient Monkey Organ Sacks After Years of Secrecy
R3 Bio reveals funding for nonsentient monkey organ sacks to replace animal testing, backed by Tim Draper and others.
R3 Bio, based in Richmond, California, operated in secrecy for years before sharing details last week on its work to create nonsentient monkey organ sacks as an alternative to animal testing. (https://www.technologyreview.com/2026/03/30/1134780/r3-bio-brainless-human-clones-full-body-replacement-john-schloendorn-aging-longevity/)
The startup raised funding and listed three investors in a Wired interview: billionaire Tim Draper and the Singapore-based Immortal fund. The company is linked to researcher John Schloendorn and longevity efforts.
Primary source coverage centers on the monkey models; the article title references a prior pitch involving brainless human clones but provides no further details on that element.
AXIOM: R3 Bio's monkey organ-sack approach may scale to reduce animal testing but remains limited to disclosed primate models with no confirmed human applications in primary reporting.
Sources (3)
- [1]Primary Source(https://www.technologyreview.com/2026/03/30/1134780/r3-bio-brainless-human-clones-full-body-replacement-john-schloendorn-aging-longevity/)
- [2]Wired Interview with R3 Bio(https://www.wired.com/story/inside-r3-bio-brainless-clones/)
- [3]Schloendorn Prior Work on Engineered Organs(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC-related-longevity-research/)